Market
McKinsey making additional settlements related to opioid crisis by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from McKinsey or federal court records
Story
McKinsey to Pay $650 Million to Settle U.S. Opioid Investigation Linked to Purdue Pharma, Enters Deferred Prosecution Agreement
Dec 13, 2024, 02:58 PM
McKinsey & Company has agreed to pay $650 million to settle a U.S. Department of Justice investigation into its consulting work with Purdue Pharma, the maker of OxyContin. The settlement addresses allegations that McKinsey aided Purdue in boosting sales of opioid painkillers, contributing to the ongoing opioid crisis in the United States. As part of the resolution, McKinsey will enter into a five-year deferred prosecution agreement, which allows the firm to avoid criminal charges while acknowledging its role in the opioid epidemic. The settlement was announced during a news conference held at the Moakley Federal Courthouse in Boston, where federal prosecutors outlined the terms of the agreement. This resolution marks a significant moment in the broader legal scrutiny of consulting firms' involvement in the opioid crisis.
View original story
Similar markets
$1.5 billion to $2 billion • 25%
Less than $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $2 billion • 25%
Federal Trade Commission • 25%
U.S. Department of Justice • 25%
Securities and Exchange Commission • 25%
Other • 25%
Johnson & Johnson • 25%
Other • 25%
Endo International • 25%
Teva Pharmaceuticals • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
No impact on business operations • 25%
Improvement in business operations • 25%
Significant decline in business operations • 25%
Minor impact on business operations • 25%
File for bankruptcy again • 25%
Reach new settlements with other firms • 25%
No significant actions • 25%
Rebrand or restructure • 25%